No angina or myocardial infarction within 182 days of registration; in view of potential cardiac risk with lenalidomide, patients with stable angina will be excluded
History of myocardial infarction or unstable angina within 12 months prior to day 1
Patients with myocardial infarction or unstable angina < 6 months prior to starting study drug
Unstable angina or myocardial infarction.
Must not have a history of myocardial infarction, severe or unstable angina, peripheral vascular disease or familial QT prolongation
Myocardial infarction of unstable angina within 6 months prior to the planned start date of study drug.
Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol e.g. unstable angina, myocardial infarction within 6 months, severe infection, etc.
Myocardial infarction or unstable angina within 6 months of the first date of treatment on this study.
History of cerebral vascular accident, unstable angina, myocardial infarction, or ventricular arrhythmia within the last 6 months
Having known myocardial infarction or unstable angina within 6 months before first ZW25 dosing
History of myocardial infarction or unstable angina within 6 months of registration
History of myocardial infarction or unstable angina within 6 months prior to day 1
Has a history of myocardial infarction or unstable angina within 6 months before enrollment
Patients with unstable angina and/or myocardial infarction within 6 months prior to screening
History of myocardial infarction or unstable angina within 6 months prior to first study treatment
Unstable angina or a history of myocardial ischemia within prior 6 months
History of myocardial infarction or unstable angina within 3 months prior to cycle 1, day 1
Myocardial infarction or unstable angina within 6 months of enrollment
Myocardial infarction within the past 12 months, or stable or unstable angina
History of myocardial infarction or severe unstable angina
Patients with a history of myocardial infarction, unstable angina, or uncontrolled arrhythmia within 3 months from enrollment.
History of myocardial infarction or unstable angina within 6 months prior to study enrollment
History of myocardial infarction or unstable angina within the past 12 months
History of myocardial infarction or unstable angina within 6 months prior to day 1
Patients with a myocardial infarction or unstable angina within 6 months of study entry
Unstable angina or a history of myocardial ischemia within prior 6 months
Myocardial infarction or uncontrolled angina within 6 months
History of a stroke, myocardial infarction, or unstable angina in the previous 6 months
Has a medical history of myocardial infarction or unstable angina
History of myocardial infarction within 6 months or unstable angina within the past 6 months.
History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months
Myocardial infarction or unstable angina less than 6 months before registration
History of myocardial infarction or unstable angina within 6 months prior to Day 1
Must not have a history of myocardial infarction, severe or unstable angina, or peripheral vascular disease
Myocardial infarction or unstable angina < 6 months prior to registration
History of myocardial infarction or unstable angina within 6 months prior to study enrollment
Unstable angina and/or myocardial infarction within 6 months prior to screening
History of myocardial infarction (within 12 months) or unstable angina (within 6 months) prior to study enrolment.
Patients are excluded if they have a history of myocardial infarction or unstable angina within 6 months prior to randomization
History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months;
Unstable angina or new-onset angina (begun within the last 3 months), or myocardial infarction within the 6 months prior to enrollment
Myocardial infarction or unstable angina within 6 months prior to registration.
Diagnosis of unstable angina or myocardial infarction within 6 months of study entry
Patients with a history of stroke, myocardial infarction, or unstable angina within 6 months prior to registration are not eligible
Myocardial infarction or unstable angina within 6 months prior to Day 1 of the study.
Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months) or myocardial infarction less than 6 months prior to randomization
History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months
Myocardial infarction or unstable angina within 6 months prior to the first dose of study drug.
History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months prior to first dose of study drug
History of myocardial infarction or unstable angina within 6 months prior to study Day
History of myocardial infarction or unstable angina within 6 months prior to day 1
History of myocardial infarction or unstable angina within 6 months prior to day -3
Patients with myocardial infarction or unstable angina =< 6 months prior to starting study drug
Patients with myocardial infarction or unstable angina =< 6 months prior to registration
History of myocardial infarction or unstable angina within 12 months prior to day 1
History of myocardial infarction or unstable angina within 6 months prior to enrollment.
Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction less than 6 months before start of study treatment
Myocardial infarction or uncontrolled angina within 3 months;
History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months
History of myocardial infarction or unstable angina within 6 months prior to Day 1
Active coronary artery disease, unstable or newly diagnosed angina or myocardial infarction less than 6 months prior to first study drug administration
Has a medical history of myocardial infarction or unstable angina.
History of myocardial infarction or unstable angina within 6 months prior to first study treatment
unstable angina or myocardial infarction within 6 months of enrollment.
Patients with myocardial infarction or unstable angina =< 6 months prior to starting study drug
Patients with myocardial infarction or unstable angina ? 6 months prior to starting study drug.
Myocardial infarction or unstable angina < 6 months prior to enrollment
History of unstable angina or myocardial infarction within 12 months prior to Day 1 or ischemic heart disease.
Myocardial infarction, severe angina, or unstable angina within 6 months prior to administration of first dose of study drug
History of myocardial infarction within 6 months prior to Cycle 1, Day 1, or history of unstable angina
History of myocardial infarction or unstable angina within 6 months of enrollment
Unstable angina or myocardial infarction within 6 months prior to first dose
History of myocardial infarction, acute inflammatory heart disease, unstable angina, or uncontrolled arrhythmia within the past 6 months.
History of myocardial infarction, severe or unstable angina, peripheral vascular disease or familial QTc prolongation.
Transmural myocardial infarction or unstable angina within 3 months prior to study registration
History of myocardial infarction or uncontrolled angina within 12 months prior to administration of study drug
Myocardial infarction or unstable angina within 6 months prior to the first administration of study drug;
Unstable angina or myocardial infarction within 6 months of enrolment,
History of myocardial infarction within 6 months before Cycle 1, Day 1, or history of unstable angina
Myocardial infarction or unstable angina within 6 months of day 1 prior to registration
Significant cardiovascular diseases (i.e., hypertension not controlled by medical therapy, unstable angina, history of myocardial infarction within the past 6 months,
History of a stroke, myocardial infarction, or unstable angina in the previous 6 months
Significant cardiovascular disease, such as cardiac disease, myocardial infarction within the previous 3 months, unstable arrhythmias, or unstable angina
History of myocardial infarction or unstable angina within 6 months prior to day 1
Myocardial infarction or unstable angina within 6 or 1 month of starting nintedanib treatment, respectively
History of unstable angina or myocardial infarction in the last week
History of unstable angina or myocardial infarction 1 month prior to study enrollment
History of myocardial infarction or unstable angina within 12 months prior to day 1
No unstable angina, regular use of nitroglycerin for exertional angina, or myocardial infarction (MI) within the last 12 months
History of unstable angina or myocardial infarction 1 month prior to study enrollment
History of unstable angina or myocardial infarction 1 month prior to study enrollment
Patients with myocardial infarction or unstable angina < 6 months prior to starting study
Medically eligible to use nicotine replacement therapy (patient currently hospitalized with acute myocardial infarction/ST elevation myocardial infarction [STEMI], unstable angina, uncontrolled arrhythmia, stroke, peripheral arterial disease vascular surgery will not be eligible for inclusion)
Subjects with a history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control
Subjects with a history of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control
